Traws Pharma advances broad-spectrum antiviral targeting Hantavirus and Ebola

Traws Pharma announced development of a novel dual-mechanism combination antiviral therapy designed to treat Hantavirus, Ebola, and Lassa virus infections, with plans to engage CDC and international health authorities for accelerated clinical development. The company is simultaneously scaling manufacturing capacity to enable rapid deployment for outbreak response and potential stockpiling.